These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 17475963)
1. Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. Kim SY; Roh JL; Kim MR; Kim JS; Choi SH; Nam SY; Lee SW; Kim SB J Nucl Med; 2007 May; 48(5):752-7. PubMed ID: 17475963 [TBL] [Abstract][Full Text] [Related]
2. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Machtay M; Natwa M; Andrel J; Hyslop T; Anne PR; Lavarino J; Intenzo CM; Keane W Head Neck; 2009 Feb; 31(2):195-201. PubMed ID: 19107945 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus. Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554 [TBL] [Abstract][Full Text] [Related]
5. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
6. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Omloo JM; Sloof GW; Boellaard R; Hoekstra OS; Jager PL; van Dullemen HM; Fockens P; Plukker JT; van Lanschot JJ Endoscopy; 2008 Jun; 40(6):464-71. PubMed ID: 18543134 [TBL] [Abstract][Full Text] [Related]
7. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056 [TBL] [Abstract][Full Text] [Related]
8. 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. Roh JL; Pae KH; Choi SH; Kim JS; Lee S; Kim SB; Nam SY; Kim SY Eur J Surg Oncol; 2007 Aug; 33(6):790-5. PubMed ID: 17306956 [TBL] [Abstract][Full Text] [Related]
9. Utility of 18F-fluorodeoxyglucose positron emission tomography in the preoperative staging of squamous cell carcinoma of the oropharynx. Kim MR; Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY Eur J Surg Oncol; 2007 Jun; 33(5):633-8. PubMed ID: 17391904 [TBL] [Abstract][Full Text] [Related]
10. Metabolic tumor volumes by [18F]-fluorodeoxyglucose PET/CT correlate with occult metastasis in oral squamous cell carcinoma of the tongue. Chung MK; Jeong HS; Son YI; So YK; Park GY; Choi JY; Hyun SH; Kim HJ; Ko YH; Baek CH Ann Surg Oncol; 2009 Nov; 16(11):3111-7. PubMed ID: 19609618 [TBL] [Abstract][Full Text] [Related]
11. Impact of positron emission tomography with the use of fluorodeoxyglucose on response to induction chemotherapy in patients with oropharyngeal and hypopharyngeal squamous cell carcinoma. Kawakita D; Masui T; Hanai N; Ozawa T; Hirakawa H; Terada A; Nishio M; Hosoi H; Hasegawa Y Acta Otolaryngol; 2013 May; 133(5):523-30. PubMed ID: 23679812 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer. Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269 [TBL] [Abstract][Full Text] [Related]
13. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Vesselle H; Freeman JD; Wiens L; Stern J; Nguyen HQ; Hawes SE; Bastian P; Salskov A; Vallières E; Wood DE Clin Cancer Res; 2007 Jun; 13(11):3255-63. PubMed ID: 17545531 [TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443 [TBL] [Abstract][Full Text] [Related]
15. Preoperative risk stratification using (18)F-FDG PET/CT in women with endometrial cancer. Lee HJ; Ahn BC; Hong CM; Song BI; Kim HW; Kang S; Jeong SY; Lee SW; Lee J Nuklearmedizin; 2011; 50(5):204-13. PubMed ID: 21727990 [TBL] [Abstract][Full Text] [Related]
16. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Seo S; Hatano E; Higashi T; Hara T; Tada M; Tamaki N; Iwaisako K; Ikai I; Uemoto S Clin Cancer Res; 2007 Jan; 13(2 Pt 1):427-33. PubMed ID: 17255262 [TBL] [Abstract][Full Text] [Related]
17. Utility of response evaluation to neo-adjuvant chemotherapy by (18)F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma. Makino T; Miyata H; Yamasaki M; Fujiwara Y; Takiguchi S; Nakajima K; Higuchi I; Hatazawa J; Mori M; Doki Y Surgery; 2010 Nov; 148(5):908-18. PubMed ID: 20378140 [TBL] [Abstract][Full Text] [Related]
18. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094 [TBL] [Abstract][Full Text] [Related]
19. Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes. Lee HY; Lee KS; Park J; Han J; Kim BT; Kwon OJ; Ahn YC; Ahn MJ; Park K; Kim J; Shim YM Acad Radiol; 2012 Apr; 19(4):440-5. PubMed ID: 22265854 [TBL] [Abstract][Full Text] [Related]
20. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT. Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]